Stem Cell Technology in Breast Cancer: Current Status and Potential Applications

Overview

Journal Stem Cells Cloning

Publisher Dove Medical Press

Specialty Biotechnology

Date 2016 May 25

PMID 27217783

Citations 8

Authors

Rena Chiotaki

Hara Polioudaki

Panayiotis A Theodoropoulos

Affiliations

Soon will be listed here.

Abstract

Breast cancer, the leading cause of cancer among females, is supported by the presence of a rare subset of undifferentiated cells within the tumor, identified as breast cancer stem cells (BCSCs). BCSCs underlie the mechanisms of tumor initiation and sustenance and are implicated in the dissemination of the primary tumor to metastatic sites, as they have been found circulating in the blood of breast cancer patients. The discovery of BCSCs has generated a great amount of interest among the scientific community toward their isolation, molecular characterization, and therapeutic targeting. In this review, after summarizing the literature on molecular characterization of BCSCs and methodologies used for their isolation, we will focus on recent data supporting their molecular and functional heterogeneity. Additionally, following a synopsis of the latest approaches for BCSC targeting, we will specifically emphasize on the therapeutic use of naïve or engineered normal stem cells in the treatment of breast cancer and present contradictory findings challenging their safety.

Citing Articles

Tumour Stem Cells in Breast Cancer.

Ibragimova M, Tsyganov M, Litviakov N Int J Mol Sci. 2022; 23(9).

PMID: 35563449 PMC: 9099719. DOI: 10.3390/ijms23095058.

Signaling pathways governing breast cancer stem cells behavior.

Song K, Farzaneh M Stem Cell Res Ther. 2021; 12(1):245.

PMID: 33863385 PMC: 8052733. DOI: 10.1186/s13287-021-02321-w.

Astaxanthin Reduces Stemness Markers in BT20 and T47D Breast Cancer Stem Cells by Inhibiting Expression of Pontin and Mutant p53.

Ahn Y, Kim M, Kim Y, An W Mar Drugs. 2020; 18(11).

PMID: 33233699 PMC: 7699712. DOI: 10.3390/md18110577.

Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review.

Dzobo K, Senthebane D, Ganz C, Thomford N, Wonkam A, Dandara C Cells. 2020; 9(8).

PMID: 32823711 PMC: 7464860. DOI: 10.3390/cells9081896.

Dual-procedural separation of CTCs in cutaneous melanoma provides useful information for both molecular diagnosis and prognosis.

Tucci M, DOronzo S, Mannavola F, Felici C, Lovero D, Cafforio P Ther Adv Med Oncol. 2020; 12:1758835920905415.

PMID: 32206092 PMC: 7074504. DOI: 10.1177/1758835920905415.

References

Gener P, Gouveia L, Sabat G, Rafael D, Fort N, Arranja A . Fluorescent CSC models evidence that targeted nanomedicines improve treatment sensitivity of breast and colon cancer stem cells. Nanomedicine. 2015; 11(8):1883-92. DOI: 10.1016/j.nano.2015.07.009. View

Shackleton M, Quintana E, Fearon E, Morrison S . Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell. 2009; 138(5):822-9. DOI: 10.1016/j.cell.2009.08.017. View

Kim Y, Liu Y, Li S, Rohrs J, Zhang R, Zhang X . Co-Eradication of Breast Cancer Cells and Cancer Stem Cells by Cross-Linked Multilamellar Liposomes Enhances Tumor Treatment. Mol Pharm. 2015; 12(8):2811-22. DOI: 10.1021/mp500754r. View

Meyer M, Fleming J, Lin A, Hussnain S, Ginsburg E, Vonderhaar B . CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer. Cancer Res. 2010; 70(11):4624-33. PMC: 4129519. DOI: 10.1158/0008-5472.CAN-09-3619. View

Voon D, Wang H, Koo J, Nguyen T, Hor Y, Chu Y . Runx3 protects gastric epithelial cells against epithelial-mesenchymal transition-induced cellular plasticity and tumorigenicity. Stem Cells. 2012; 30(10):2088-99. DOI: 10.1002/stem.1183. View

Bock C, Rack B, Huober J, Andergassen U, Jeschke U, Doisneau-Sixou S . Distinct expression of cytokeratin, N-cadherin and CD133 in circulating tumor cells of metastatic breast cancer patients. Future Oncol. 2014; 10(10):1751-65. DOI: 10.2217/fon.14.58. View

Owens T, Naylor M . Breast cancer stem cells. Front Physiol. 2013; 4:225. PMC: 3753536. DOI: 10.3389/fphys.2013.00225. View

Schatton T, Murphy G, Frank N, Yamaura K, Waaga-Gasser A, Gasser M . Identification of cells initiating human melanomas. Nature. 2008; 451(7176):345-9. PMC: 3660705. DOI: 10.1038/nature06489. View

Eirew P, Stingl J, Raouf A, Turashvili G, Aparicio S, Emerman J . A method for quantifying normal human mammary epithelial stem cells with in vivo regenerative ability. Nat Med. 2008; 14(12):1384-9. DOI: 10.1038/nm.1791. View

10.

Vieira A, Ricardo S, Ablett M, Dionisio M, Mendes N, Albergaria A . P-cadherin is coexpressed with CD44 and CD49f and mediates stem cell properties in basal-like breast cancer. Stem Cells. 2012; 30(5):854-64. DOI: 10.1002/stem.1075. View

11.

Nagaiah G, Abraham J . Circulating tumor cells in the management of breast cancer. Clin Breast Cancer. 2010; 10(3):209-16. DOI: 10.3816/CBC.2010.n.028. View

12.

Reuben J, Lee B, Gao H, Cohen E, Mego M, Giordano A . Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24lo cancer stem cell phenotype. Eur J Cancer. 2011; 47(10):1527-36. PMC: 3116032. DOI: 10.1016/j.ejca.2011.01.011. View

13.

Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S . Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell. 2010; 140(1):62-73. DOI: 10.1016/j.cell.2009.12.007. View

14.

Chiotaki R, Polioudaki H, Theodoropoulos P . Cancer stem cells in solid and liquid tissues of breast cancer patients: characterization and therapeutic perspectives. Curr Cancer Drug Targets. 2015; 15(3):256-69. DOI: 10.2174/1568009615666150211102503. View

15.

Dalerba P, Dylla S, Park I, Liu R, Wang X, Cho R . Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A. 2007; 104(24):10158-63. PMC: 1891215. DOI: 10.1073/pnas.0703478104. View

16.

Hardt O, Wild S, Oerlecke I, Hofmann K, Luo S, Wiencek Y . Highly sensitive profiling of CD44+/CD24- breast cancer stem cells by combining global mRNA amplification and next generation sequencing: evidence for a hyperactive PI3K pathway. Cancer Lett. 2012; 325(2):165-74. DOI: 10.1016/j.canlet.2012.06.010. View

17.

Castano Z, Fillmore C, Kim C, McAllister S . The bed and the bugs: interactions between the tumor microenvironment and cancer stem cells. Semin Cancer Biol. 2012; 22(5-6):462-70. PMC: 3445659. DOI: 10.1016/j.semcancer.2012.04.006. View

18.

Chang M, Oh B, Rhee Y, Lee S . Doxycycline supplementation allows for the culture of human ESCs/iPSCs with media changes at 3-day intervals. Stem Cell Res. 2015; 15(3):608-613. DOI: 10.1016/j.scr.2015.10.007. View

19.

Krawczyk N, Meier-Stiegen F, Banys M, Neubauer H, Ruckhaeberle E, Fehm T . Expression of stem cell and epithelial-mesenchymal transition markers in circulating tumor cells of breast cancer patients. Biomed Res Int. 2014; 2014:415721. PMC: 4034492. DOI: 10.1155/2014/415721. View

20.

Fehm T, Becker S, Duerr-Stoerzer S, Sotlar K, Mueller V, Wallwiener D . Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res. 2007; 9(5):R74. PMC: 2242672. DOI: 10.1186/bcr1783. View